title: Neuropeptides contribute to peripheral nociceptive sensitization by regulating interleukin-1β production in keratinocytes.
abstract: BACKGROUND
  It is increasingly evident that there is a close connection between the generation of cutaneous inflammatory cytokines and elevated neuropeptide signaling in complex regional pain syndrome (CRPS) patients. Previously, we observed in the rat tibia fracture model of CRPS that activation of caspase-1 containing NALP1 inflammasomes was required for interleukin (IL)-1β production in keratinocytes, and that administration of an IL-1 receptor antagonist (anakinra) reduced the fracture-induced hindpaw mechanical allodynia. We therefore hypothesized that neuropeptides lead to nociceptive sensitization through activation of the skin's innate immune system by enhancing inflammasome expression and caspase-1 activity.
  
  
  METHODS
  We determined whether the neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) require IL-1β to support nociceptive sensitization when injected into mouse hindpaw skin by testing mechanical allodynia. We then investigated whether these neuropeptides could stimulate production of IL-1β in a keratinocyte cell line (REKs), and could increase the expression of inflammasome component proteins including NALP1 and caspase-1. Finally, we determined whether neuropeptide-stimulated IL-1β production required activation of caspase-1 and cathepsin B.
  
  
  RESULTS
  Intraplantar injections of SP and CGRP lead to allodynia in mouse hindpaws but CGRP was approximately 10-fold less potent in causing this response. Moreover, systemic administration of the IL-1 receptor (IL-1R) antagonist anakinra prevented sensitization after neuropeptide injection. Also, mouse skin keratinocytes express IL-1R, which is up-regulated after local neuropeptide application. In vitro data demonstrated that both SP and CGRP increased IL-1β gene and protein expression in REKs in a dose-dependent manner. Furthermore, SP time- and dose-dependently up-regulated NALP1 and caspase-1 mRNA and protein levels in REKs. In contrast, CGRP time- and dose-dependently enhanced NALP1 and caspase-1 mRNA levels without causing a significant change in NALP1 or caspase-1 protein expression in REKs. Inhibition of caspase-1 activity using the selective inhibitor Ac-YVAD-CHO reduced SP and, less effectively, CGRP induced increases in IL-1β production in REK cells. The selective cathepsin B inhibitor CA-74Me inhibited neuropeptide induced IL-1β production in REKs as well.
  
  
  CONCLUSIONS
  Collectively, these results demonstrate that neuropeptides induce nociceptive sensitization by enhancing IL-1 β production in keratinocytes. Neuropeptides rely on both caspase-1 and cathepsin B for this enhanced production. Neurocutaneous signaling involving neuropeptide activation of the innate immunity may contribute to pain in CRPS patients.
authors: Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
authors: Xiaoyou
authors: X
authors: Shi
authors: Liping
authors: L
authors: Wang
authors: Xiangqi
authors: X
authors: Li
authors: Peyman
authors: P
authors: Sahbaie
authors: Wade S
authors: WS
authors: Kingery
authors: J David
authors: JD
authors: Clark
references: Pathobiology. 1999;67(1):51-4
references: 9873229
references: Glia. 2010 Jan 1;58(1):114-24
references: 19544382
references: Nat Immunol. 2009 Mar;10(3):241-7
references: 19221555
references: J Rheumatol. 2003 Jan;30(1):146-50
references: 12508404
references: Eur J Med Res. 2009 Mar 17;14(3):130-5
references: 19380284
references: Pain. 2004 Mar;108(1-2):95-107
references: 15109512
references: Int Rev Neurobiol. 2007;82:407-21
references: 17678975
references: Neurosci Lett. 2004 Apr 22;360(1-2):61-4
references: 15082179
references: J Invest Dermatol. 1999 May;112(5):818-21
references: 10233778
references: J Invest Dermatol. 1993 Aug;101(2):118-26
references: 7688400
references: Anesthesiology. 2006 Jun;104(6):1274-82
references: 16732100
references: Pain. 2009 Oct;145(3):341-349
references: 19660865
references: Pain. 2009 Dec 15;147(1-3):277-86
references: 19853379
references: Pain. 2009 Aug;144(3):303-313
references: 19473768
references: Mediators Inflamm. 2002 Feb;11(1):47-51
references: 11930962
references: FEBS Lett. 1998 Nov 6;438(3):150-8
references: 9827536
references: Brain Behav Immun. 2008 Oct;22(7):1072-1077
references: 18442892
references: J Invest Dermatol. 1999 Jun;112(6):843-52
references: 10383728
references: Mol Cell. 2007 Mar 9;25(5):713-24
references: 17349957
references: J Neurosci Methods. 1994 Jul;53(1):55-63
references: 7990513
references: Trends Pharmacol Sci. 2007 Sep;28(9):465-72
references: 17692395
references: Cell Death Differ. 2003 Sep;10(9):956-68
references: 12934070
references: N Engl J Med. 2007 Mar 22;356(12):1216-25
references: 17377159
references: Regul Pept. 2006 Dec 10;137(3):134-9
references: 16904202
references: Can J Physiol Pharmacol. 2007 Jun;85(6):613-20
references: 17823623
references: J Histochem Cytochem. 2007 May;55(5):443-52
references: 17164409
references: Biochem J. 1992 Jan 1;281 ( Pt 1):175-7
references: 1731753
references: Nat Rev Mol Cell Biol. 2003 Feb;4(2):95-104
references: 12563287
references: Anesthesiology. 2010 Oct;113(4):945-56
references: 20823759
references: Pain. 2008 Sep 30;139(1):15-27
references: 18396374
references: Pain. 2009 Aug;144(3):278-286
references: 19464118
references: J Invest Dermatol. 1983 Feb;80(2):124-30
references: 6185597
references: Infect Immun. 2009 Oct;77(10):4327-36
references: 19635822
references: Clin J Pain. 2006 Mar-Apr;22(3):235-9
references: 16514322
references: Int J Mol Med. 2003 May;11(5):635-9
references: 12684703
references: Genome Res. 2008 Jul;18(7):1112-26
references: 18562681
references: J Neurosci. 2008 Dec 24;28(52):14062-73
references: 19109489
references: Exp Neurol. 2009 Jun;217(2):395-400
references: 19341730
references: Neuropeptides. 2006 Aug;40(4):251-63
references: 16904178
references: Nat Clin Pract Rheumatol. 2008 Jan;4(1):34-42
references: 18172447
references: Neuroscience. 2003;121(4):999-1005
references: 14580950
references: Arthritis Res Ther. 2006;8(6):220
references: 17118212
references: Brain Res Rev. 2009 Apr;60(1):57-64
references: 19166877
references: Cell Host Microbe. 2008 Sep 11;4(3):198-208
references: 18779046
references: Biochemistry. 1994 Apr 5;33(13):3934-40
references: 8142397
references: Neurosci Lett. 2004 Apr 15;359(3):163-6
references: 15050689
references: Brain Res. 2009 Mar 31;1263:43-9
references: 19368813
references: Immunol Rev. 2009 Jan;227(1):95-105
references: 19120479
references: Neurosci Lett. 2008 Jun 6;437(3):199-202
references: 18423863